OneMedForumNY 2013, June 26-27
PDUFA: Kadcyla, Immunogen – Metastasized Breast Cancer
March 2013: Santarus’ Uceris – Ulcerative Colitis
PDUFA: March 31 – Invokana
The US Food and Drug advisory panel has voted for the preliminary approval of Invokana (canagliflozin), Johnson and Johnson’s new type 2 diabetes drug, in a 10 to 5 vote. On the table during the discussion for this potentially innovative drug was the concern that it has significant
PDUFA: Dec 21– Alexza Pharmaceuticals Inc.
Alexza Pharmaceuticals Inc. [NASDAQ: ALXA] expects an FDA decision under the Prescription Drug User Fee Act (PDUFA) on the approval status of ADASUVE, being developed for schizophrenia or bipolar I disorder in adults.
Alexza Pharmaceuticals is an emerging pharmaceutical comp
PDUFA: Dec. 20 — Hemispherx Biopharma
Hemispherx Biopharma [NYSE: HEB] expects an FDA decision under the Prescription Drug User Fee Act (PDUFA) concerning the approval status of Ampligen (poly Izpoly C12U), being developed for the treatment of chronic fat
Earnings Release: 11/25 — China Nuokang Bio-Pharmaceutical Inc.
China Nuokang Bio-Pharmaceutical Inc. [NASDAQ: NKBP] has announced that the company plans to release third quarter 2012 financial results on Sunday, November 25, 2012.
Nuokang is a leading biopharmaceutical company foc
Forward Stock Split — Sept 24, Medivation, Inc
Medivation, Inc [Nasdaq: MDVN] today announced that it has effected a 2-for-1 forward split of all shares of its common stock and increased the authorized number of shares of common stock.
View the full press release
PDUFA: Sept 30 — NPS Pharmaceuticals
PDUFA: Oct 16 — Santarus, Inc **Extended to January 16, 2013**
Santarus, Inc. expects an FDA decision under the Prescription Drug User Fee Act (PDUFA) on the approval status of UCERIS, being developed for the treatment of induction of remission of mild to moderate active ulcerative colitis.
Santarus, Inc. is a specialty biopharmaceutica
PDUFA: Oct 19 — Supernus Pharmaceuticals
Supernus Pharmaceuticals [Nasdaq: SUPN] expects an FDA decision under the Prescription Drug User Fee Act (PDUFA) on the approval status of SPN-804, being developed for the treatment of epilepsy.
Supernus Pharmaceuticals is a sp
August 6-8, 2012 Drug & Diagnostic Development Week
August 06-08, 2012 · The Westin San Francisco Market Street · San Francisco, CA
A new paradigm in drug and diagnostic development is emerging. Exciting scientific discoveries in genome biology and technology are paving the way to new product development and commercial opport